Item 1.01 Entry into a Material Definitive Agreement
On
The gross proceeds to the Company from the transactions are
The Shares (but not the Warrants or shares of Common Stock issuable upon
exercise of the Warrants) were offered and sold by the Company pursuant to an
effective shelf registration statement on Form S-3, which was filed with the
The Warrants and the shares issuable upon exercise of the Warrants are being sold and issued without registration under the Securities Act of 1933, as amended (the "Securities Act"), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.
The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the Purchase Agreement is filed with this report only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.
The Company also entered into an engagement letter (the "Engagement Letter") on
The forms of the Purchase Agreement, the Warrant and the Placement Agent Warrant, as well as the Engagement Letter, are filed as Exhibits 10.1, 4.1, 4.2 and 10.2, respectively, to this Current Report on Form 8-K. The foregoing summaries of the
1
--------------------------------------------------------------------------------
terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.
A copy of the opinion of
Item 3.02 Unregistered Sales of
The information contained above in Item 1.01 related to the Warrants and the Placement Agent Warrants and the shares of Common Stock issuable thereunder is hereby incorporated by reference into this Item 3.02.
Item 8.01 Other Events
On
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 4.1 Form of Warrant 4.2 Form of Placement Agent Warrant 5.1 Legal Opinion ofLatham & Watkins LLP 10.1 Form of Securities Purchase Agreement 10.2 Engagement Letter betweenOncternal Therapeutics, Inc. and H.C.Wainwright & Co., LLC , dated as ofMay 15, 2020 23.1 Consent ofLatham & Watkins LLP (included in Exhibit 5.1) 99.1 Press Release issued byOncternal Therapeutics, Inc. onMay 20, 2020
Cautionary Note Regarding Forward-Looking Statements
Oncternal cautions you that statements included in this report that are not a
description of historical facts are forward-looking statements. In some cases,
you can identify forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "anticipate," "could," "intend," "target,"
"project," "contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negatives of these terms or other similar expressions. These
statements are based on the Company's current beliefs and expectations. These
statements are based on the Company's current beliefs and
expectations. Forward-looking statements include statements regarding: the
completion of the registered direct offering, the satisfaction of customary
closing conditions related to the registered direct offering and the intended
use of net proceeds from the registered direct offering. The inclusion of
forward-looking statements should not be regarded as a representation by
Oncternal that any of its plans will be achieved. Actual results may differ from
those set forth in this release due to the risks and uncertainties inherent in
Oncternal's business, including, without limitation: market and other
conditions; and other risks described in the Company's prior press releases as
well as in public periodic filings with the
2
--------------------------------------------------------------------------------
© Edgar Online, source